Pediatric multisystem SARS COV2 with versus without cardiac involvement: a multicenter study from Latin America

Ricardo Pignatelli 1 · Clara Vazquez Antona 2 · Ivan Romero Rivera 3 · Patricia Alvarez Zenteno 4 · Yanet Toribio Acosta 5 · Manuel Huertas-Quinones 6 · Carlos Alvarez Murillo 7 · Franklin Mendoza Torres 7 · Carlos Fernandez Cabalin 8 · Ana Galvan Camacho 9 · Alex Alcantara Perez 10 · Ana Braga Lombardi 11 · Andressa Mussi Soares 12 · Carolina Torres Garcia 13 · Cibelle Teixeira Borges 14 · Claudia Natalia Villalba 15 · Cristhian Ramirez Lechado 16 · Deborah Trevisan Dias 17 · Diana Aravena Morales 18 · Elizabeth Mora Copete 19 · Guillermo Larios Goldenberg 20 · Jahaia Sussety Salazar 21 · Jessica Alchundia Moreira 21 · Junko Asakura 22 · Karla Solorzano Sabando 21 · Klebia Castello Branco 23 · Lida Toro Rosas 10 · Magna Pereira Duarte 24 · Maria Jimenez Carbajal 25 · Martha Rubio Hernandez 26 · Moises Mier Martinez 27 · Nancy Garay Echeverria 28 · Olga Maza Caneva 29 · Patricia Romero Sepulveda 30 · Paulina Agurto Diaz 18 · Ruth Rugel Pluas 31 · Theo Contreras Alvarado 32 · Lorena Tapia Faundes 33 · Yeny Briones Diaz 18 · Justin P. Zachariah 1

Received: 9 February 2021 / Revised: 18 March 2021 / Accepted: 21 March 2021 / Published online: 1 April 2021

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract

Latin America (LATAM) children offer special insight into Severe Acute Respiratory Syndrome Coronavirus 2 (SARS COV2) due to high-risk race/ethnicity, variability in medical resources, diverse socioeconomic background, and numerous involved organ systems. This multinational study of LATAM youth examined the distinguishing features of acute or late multisystem SARS COV2 with versus without cardiac involvement. A consecutive sample of youth 0–18 years old (N = 98; 50% male) presenting with multisystem SARS COV2 to 32 centers in 10 Latin American countries participating in a pediatric cardiac multi-imaging society were grouped as with versus without cardiac involvement, defined as abnormal echocardiographic findings or arrhythmia. Collected clinical data were analyzed by Student’s t-test or Fisher’s exact test. Cardiac (N = 48, 50% male) versus no cardiac (N = 50, 50% male) were similar in age; weight; nonrespiratory symptoms; and medical history. The cardiac group had 1 death and symptoms including coronary artery dilation, ejection fraction <50%, pericardial effusion, peripheral edema, arrhythmia, and pulmonary artery thrombus. The cardiac group had higher risk of ICU admission (77% vs 54%, p = 0.02); invasive ventilation (23% vs 4%, p = 0.007); vasoactive infusions (27% vs 4%, p = 0.002); prominent respiratory symptoms (60% vs 36%, p < 0.03); abnormal chest imaging (69% vs 34%, p = 0.001); troponin (33% vs 12%, p = 0.01); alanine aminotransferase (33% vs 12%, p = 0.02); and thrombocytopenia (46% vs 22%, p = 0.02). Receiver operating curve analysis showed that abnormal laboratories had 94% sensitivity and 98% negative predictive value on the need for ICU interventions.

Conclusion: In LATAM children with multisystem SARS COV2, cardiac involvement was prevalent. Cardiac involvement was more likely to require ICU interventions, certain abnormal labs, and respiratory involvement.

What is Known:
• SARS COV2 can be asymptomatic in children but in some cases can have serious multisystemic involvement.
• Hispanic ethnicity is purportedly at high risk of SARS COV2 in nations where they are often disadvantaged minority populations.

What is New:
• Latin American children presenting with multisystem SARS COV2 frequently have cardiac involvement which was associated with ICU interventions; prominent respiratory symptoms; abnormal chest X-ray; elevated troponin, ALT, and thrombocytopenia.
• Elevated troponin, ALT or thrombocytopenia had high sensitivity and negative predictive value on the need for intensive care interventions.

Communicated by Peter de Winter

Justin P. Zachariah
justin.zachariah@bcm.edu

Extended author information available on the last page of the article
The novel severe acute respiratory syndrome coronavirus 2 (SARS COV2) emerged widely in December 2019 and has since become a worldwide pandemic [1–3]. Rarely, children are severely infected with multisystem involvement beyond the respiratory tract including gastrointestinal, skin, coagulation, and cardiovascular complications. This multisystem involvement may occur during acute infection or later in a new-to-medicine syndrome called PIMS (pediatric inflammatory multisystem syndrome) or MISC (multisystem inflammatory syndrome in children) [4]. Risk factors for severe consequences include aggregate factors associated with general infection spread such as healthcare system prevention programs, availability of medical interventions, socioeconomic freedom to socially distance, availability of mitigation paraphernalia, and competing health risks like alternate infections, while individual factors include race/ethnicity and past medical history factors like obesity, heart disease, cancer, and immunocompromised status [1–3]. Recent reports highlight Hispanic ethnicity as a high risk [5].

More primary data collection to guide clinical management of acute SARS COV2 or PIMS/MISC in youth is needed to formulate management responses, especially for potentially life-threatening cardiovascular complications. The need is even more acute particularly for resource-poor settings in order to identify adequate strategies and reduce unnecessary practice variation. Further disambiguation is needed between Latin American ethnicity versus other risk factors such as obesity or socioeconomic status in high per capita income countries. While previous reports have arisen from locations with high-resource medical settings like the USA and UK, health options and economic reality are quite different for SARS COV2–affected children in LATAM including from individual-specific factors intrinsic ranging to community disparities up to sociopolitical variation in response to SARS COV2. Given the variability of presentation, evolving disease definitions, and focus on symptomatic support during the advent of SARS COV2, we focused on more seriously affected LATAM children early in the pandemic presenting with high suspicion for SARS COV2. Within this group, we searched for widely assayable clinical symptoms, signs, and diagnostic investigations that would be useful to providers in variably resourced settings. This multicenter study reports the reality of multisystem, acute, or late SARS COV2 by collating isolated clinical cases of LATAM youth from 32 centers in 10 countries of Central America, South America, and Mexico. We compared these multisymptomatic children on the basis of presence versus absence of cardiac symptoms with respect to other organ system signs and symptoms, medical history and presentation, laboratory and imaging, and therapies. To focus on those with presumed PIMS/MISC, separate sensitivity analysis was performed on those with positive SARS COV2 IGG during clinic presentation.
Symptoms and signs, and management (Supplementary Table 1). SARS COV2 was defined as documented SARS COV2 test positivity, close contact with documented or suspected SARS COV2 patient, or combination of symptoms/signs consistent with SARS COV2 or sequelae. Symptoms, radiological findings, laboratory signs, and clinical management were assessed as present versus absent. Symptom ascertainment used conditional organization such that 1st-tier questions included endorsement of presence of symptoms affecting the respiratory, cardiovascular, gastrointestinal, neurological, cutaneous, abnormal laboratory, or abnormal imaging. If the presence of one of these categories was endorsed, a secondary tier of specific symptoms and tests was assayed specific to the endorsed category. Past presence of serious medical history was assessed.

**Statistical analysis**

The primary comparison was between those patients with versus without cardiovascular involvement (cardiac vs no cardiac). The cardiac group was defined as diagnosed arrhythmia including premature atrial or ventricular contractions, sustained or nonsustained atrial or ventricular tachycardias, or atrioventricular block of any degree; dilation of any coronary artery segment above body surface area–referenced z score at or above 2; LV ejection fraction below 50%; dilated LV size at or above 2 scores; qualitative assessment of moderate or greater regurgitation of atriioventricular or semilunar valves; any pericardial effusion; clinical diagnosis of myocarditis by treating provider; clinical diagnosis of peripheral edema; or vascular thrombus/embolism. Continuous data (largely limited to age and weight) were analyzed using Student’s t-test. Categorical data was analyzed using Fisher’s exact test. Receiver operator curves (ROCs) were constructed using the presence of the most strongly associated laboratory tests versus the need for ICU care, specifically inotropic infusion or mechanical ventilation. Two-sided p values less than 0.05 were considered significant. SPSS 25 (IBM, Chicago, IL) was used for statistical analyses.

**Results**

Multisystem SARS COV2 was reported from mid-May to August 2020 comprising 98 children, 48 cardiac and 50 no cardiac (Table 1). The cardiac group trended toward being younger, but otherwise similar in weight and sex. Past medical histories were similar with no obvious overrepresentation in the

| Table 1 | Multisystem SARS COV2 reported from mid-May to August 2020 |
|---------|----------------------------------------------------------|
| **Background characteristics** | **No cardiac involvement** | **Cardiac involvement** | **p value** |
| N | 50 | 48 |
| Age in years, mean (SD) | 6.1 (4.3) | 4.4 (3.9) | 0.06 |
| Male, no. (%) | 25 (50%) | 24 (50%) | 1 |
| Weight in kilograms, mean (SD) | 26.2 (15.9) | 21.2 (15.8) | 0.12 |
| Age, sex-adjusted weight percentile >85%, no. (%) | 14 (28%) | 17 (35%) | 0.52 |
| No past medical conditions, no. (%) | 32 (64%) | 26 (54%) | 0.41 |
| History of |  |
| Asthma, no. (%) | 4 (8%) | 7 (15%) | 0.35 |
| Cancer, no. (%) | 4 (9%) | 0 (0) | 0.12 |
| Complex congenital heart disease, no. (%) | 0 | 2 (5%) | 0.23 |
| Diabetes mellitus, no. (%) | 0 | 0 |
| Hypertension, no. (%) | 0 | 0 |
| Immunomodulation, no. (%) | 2 (4%) | 2 (5%) | 1 |
| Prematurity 24–36 weeks gestation, no. (%) | 1 (2%) | 2 (5%) | 0.61 |
| Close contact SARS COV2 exposure, no. (%) | 13 (26%) | 23 (48%) | 0.04 |
| SARS COV2 test–positive, no. (%) | 19 (38%) | 32 (67%) | 0.005 |
| PCR, no. (%) | 11 (22%) | 15 (31%) | 0.36 |
| IgM, no. (%) | 7 (14%) | 11 (23%) | 0.30 |
| IgG, no. (%) | 8 (16%) | 15 (31%) | 0.10 |

P values in bold italics indicate statistical significance <0.05
Immunomodulation includes patients who are immunocompromised, with solid organ transplant, and with inflammatory conditions
Abbreviations: SARS COV2 Severe Acute Respiratory Syndrome Coronavirus 2, PCR polymerase chain reaction
cardiac group for those with asthma, cancer, congenital heart disease, diabetes mellitus, hypertension, immunomodulation (defined as on immune modifying therapies or intrinsically immunocompromised), or prematurity. Congenital heart disease was present in 2 cardiac group patients, but cardiac status worsened while infected with SARS COV2. Positive SARS testing was more likely in the cardiac group. SARS COV2 IgG indicating initial SARS COV2 exposure weeks earlier was present in similar proportions of no cardiac and cardiac patients (Table 1). One infant in the cardiac group with coronary artery dilation and left ventricular dilation died.

Table 2  Cardiac patients with significantly higher number of signs and symptoms compared to noncardiac patients

| Signs and symptoms                                  | No cardiac involvement | Cardiac involvement | p value |
|-----------------------------------------------------|------------------------|---------------------|---------|
| N                                                   | 50                     | 48                  |         |
| Total count of signs and symptoms, N (SD)           | 6 (3)                  | 10 (5)              | <0.001  |
| Fever, no. (%)                                      | 37 (74%)               | 30 (63%)            | 0.28    |
| Cardiac symptoms                                    |                        |                     |         |
| Abnormal echocardiography, no. (%)                  | 39 (81%)               |                     |         |
| Coronary artery dilation, no. (%)                   | 22 (46%)               |                     |         |
| Left ventricular ejection fraction <50%, no. (%)    | 11 (23%)               |                     |         |
| Left ventricular dilation, no. (%)                  | 13 (27%)               |                     |         |
| Moderate or severe valvar regurgitation, no. (%)    | 10 (21%)               |                     |         |
| Pericardial effusion, no. (%)                       | 14 (29%)               |                     |         |
| Arrhythmia, no. (%)                                 | 6 (12%)                |                     |         |
| Myocarditis, no. (%)                                | 18 (37%)               |                     |         |
| Peripheral edema, no. (%)                          | 15 (31%)               |                     |         |
| Main pulmonary artery embolism, no. (%)            | 1 (2%)                 |                     |         |
| Respiratory symptoms, no. (%)                       | 18 (36%)               | 29 (60%)            | 0.03    |
| Accessory respiratory muscle use, no. (%)          | 6 (13%)                | 16 (37%)            | 0.01    |
| Neurological symptoms, no. (%)                      | 4 (8%)                 | 11 (23%)            | 0.05    |
| Gastrointestinal symptoms, no. (%)                 | 38 (76%)               | 31 (65%)            | 0.27    |
| Mucocutaneous symptoms, no. (%)                    | 35 (70%)               | 27 (56%)            | 0.21    |
| Abnormal labs, no. (%)                              | 34 (68%)               | 37 (77%)            | 0.37    |
| Elevated troponin I, no. (%)                        | 6 (12%)                | 16 (33%)            | 0.01    |
| Elevated BNP or proBNP, no. (%)                    | 12 (24%)               | 20 (42%)            | 0.08    |
| Creatinine estimate glomerular filtration rate <50% of predicted, no. (%) | 2 (4%)                 | 5 (10%)             | 0.26    |
| Elevated alanine aminotransferase, no. (%)         | 8 (15%)                | 18 (33%)            | 0.02    |
| Elevated D-dimer, no. (%)                           | 27 (54%)               | 28 (58%)            | 0.69    |
| Elevated partial thromboplastin time, no. (%)      | 4 (8%)                 | 6 (12%)             | 0.52    |
| Elevated procalcitonin, no. (%)                    | 10 (20%)               | 12 (25%)            | 0.63    |
| Leukocytosis, no. (%)                               | 14 (28%)               | 16 (33%)            | 0.66    |
| Thrombocytosis, no. (%)                             | 3 (6%)                 | 6 (12%)             | 0.31    |
| Elevated C reactive protein, no. (%)               | 31 (62%)               | 32 (67%)            | 0.68    |
| Leukopenia, no. (%)                                 | 6 (12%)                | 6 (12%)             | 1       |
| Thrombocytopenia, no. (%)                           | 11 (22%)               | 22 (46%)            | 0.02    |
| Abnormal chest imaging, no. (%)                    | 17 (34%)               | 33 (69%)            | 0.001   |
| Abnormal chest X-ray, no. (%)                      | 10 (20%)               | 25 (52%)            | 0.001   |
| Abnormal CT scan, no. (%)                          | 3 (6%)                 | 8 (12%)             | 0.12    |

P values in bold italics indicate statistical significance <0.05

Symptoms and signs

Cardiac patients had significantly higher number of signs and symptoms compared to noncardiac patients (Table 2). Cardiac patients (N = 48) had abnormal echocardiography in 81% specifically with coronary artery dilation in 46%, LV ejection fraction <50% in 23%, dilated LV in 27%, moderate to severe valvar regurgitation in 21%, pericardial effusion in 29%, arrhythmia in 12%, myocarditis diagnosis in 37%, peripheral edema in 31%, and pulmonary embolism in one newborn infant (Fig. 1). Cardiac patients
were significantly more likely to have respiratory symptoms generally and accessory muscle use specifically. Similar proportions in cardiac and no cardiac groups had concomitant fever, neurological symptoms, gastrointestinal symptoms, and mucocutaneous symptoms. With respect to investigations, cardiac patients were more likely to have elevated serum troponin, but similar brain natriuretic peptide (BNP)/proBNP. Elevated ALT and thrombocytopenia were also more common in the cardiac group. Indicators of kidney function, coagulation markers, inflammation markers, and leukopenia were similar between cardiac and noncardiac patients. The cardiac group was more likely to have abnormal chest imaging, specifically X-ray with pulmonary infiltrates or edema. ROCs showed the presence of either elevated troponin and ALT or thrombocytopenia, while the need for ICU interventions had an area under the curve of 0.75, 94% sensitivity, 57% specificity, 30% positive predictive value, and 98% negative predictive value. In a sensitivity analysis, the ROC for troponin alone showed 69% sensitivity, 87% specificity, 50% positive predictive value, and 93% negative predictive value. In a further sensitivity analysis isolated only to those children with SARS COV2 test positivity or documented close contact (N = 64) ROC for troponin, ALT or thrombocytopenia had sensitivity 92%, specificity 50%, positive predictive value 34%, and negative predictive value 96%.

Management

The cardiac group was more likely to need ICU admission (Table 3). While none received extracorporeal membrane oxygenation support and 27% of the combined group did not receive IVIg, the cardiac group was more likely to use vasoactive infusions, endotracheal intubation, diuretic therapy, and macrolide antibiotics. Specifically, 27% of the cardiac group children required vasoactive infusions for systemic perfusion support compared to only 4% of those in the no cardiac group (p = 0.002).

Subgroup analyses

Of the total group, 32 children (31%) were 2 years of age or younger, 21 of whom were in the cardiac group. While the limited sample precluded meaningful statistical analysis, within this younger age group, cardiac versus no cardiac children appeared similar in age, weight, male sex, and noncardiac symptom sets, lab testing, chest imaging, and therapies (data not shown).
Of the total group, 23 children (23%) were SARS COV2 IgG–positive, indicating subacute exposure, with 15 of these being cardiac. Within this group, cardiac versus no cardiac children were similar in age, weight, and sex. Noncardiac symptom sets, lab testing, chest imaging, and therapies were also grossly similar (data not shown). The subsample size precluded more detailed statistical analysis.

Discussion

This analysis of children from LATAM belonged to a purportedly high-risk race/ethnicity for SARS COV2 infection and sequelae but was drawn from countries with a variety of socioeconomic backgrounds and health systems. In this group selected for multisystem involvement, a substantial proportion were indeed proven to be SARS COV2–positive or SARS COV2–exposed, which demonstrates the global reach of SARS COV2 in the differential diagnosis of multisystem disease. Of these multisystem-affected children, nearly half had clinically significant cardiac involvement including myocarditis, coronary artery dilation, ventricular dysfunction, moderate to severe valvar regurgitation, arrhythmia, one infant with near occlusive main pulmonary thrombus, and one infant mortality. This substantial cardiac involvement was also present in the toddler/infant subgroup as well as those with remote SARS COV2 exposure noted by IgG presence. The cardiac group had more signs and symptoms generally. Specifically, the cardiac group was more likely to have prominent accessory respiratory muscle use, abnormal chest X-ray, and abnormal circulating troponin, ALT, and thrombocytopenia, but not BNP. The cardiac group was more likely to need intensive care including more endotracheal intubation and ventilation, vasoactive infusions, and diuretic therapy. ROCs showed either abnormal troponin or ALT, or thrombocytopenia was highly sensitive with high negative predictive value on the need for ICU interventions. On balance, for LATAM children presenting with multisystem SARS COV2, cardiac involvement was frequent, distinguished by worse respiratory status and cardiac enzyme elevation, thrombocytopenia, and ALT elevation, and led to intensive care support. We are unaware of other reports in LATAM children detailing neither significant multisystem involvement nor the characteristics distinguishing cardiac vs non cardiac involvement.

Contrasting perhaps from previous publications from North American and European LATAM subpopulations, these data are from LATAM children of varying socioeconomic backgrounds and are informative for clinical SARS COV2 management in LATAM children specifically and global health epidemiology generally. Emerging data shows that Hispanic adults as minority populations in certain North American or European populations may or may not be at higher risk of SARS COV2 infection, intensive care admission, or respiratory failure based on high-risk/front-line occupations, age, or other SARS COV2 risk factors such that after adjustment, most of the ethnicity-related excess risk is attenuated [6]. In this cohort of children, such risk factors were not apparent. In recent pediatric reports, serious consequences of SARS COV2 may be more common in Hispanic children [7]. Unmeasured confounders of genetics, immunologic response, detailed body composition, lifestyle, environment, or other factors cannot be excluded.

SARS COV2 infection is described to have myriad symptoms and complications in children. Early reports in Chinese children had median age 6.7 years and fever in 41%, and only 3 patients required intensive care support and invasive mechanical ventilation all of whom had preexisting conditions [8]. Reports from Italy showed that the median age was 11 years, and 51.4% of them were males, and the general hospitalization rate was 13.3%, and the ICU admission rate in intensive care unit was 3.5%. Preexisting conditions were present in 10% of hospitalized patients, and infants had the highest proportion of severe infections [1]. A subsequent multicenter report from the USA describing children needing intensive care showed that the large majority had significant preexisting conditions.

| Table 3 Cardiac and non-cardiac group involvement |
|-------|------------------|------------------|-------|
|       | Management       | No cardiac involvement | Cardiac involvement | p value |
| N     |                  | 50                | 48                |        |
| Admission to ICU, no. (%) | 27 (54%) | 37 (77%) | **0.02** |
| Antiarrhythmic, no. (%) | 0 (0) | 1 (2%) | 0.49 |
| Extracorporeal membrane oxygenation, no. (%) | 0 | 0 |        |
| Diuretic therapy, no. (%) | 3 (6%) | 19 (40%) | **<0.001** |
| Endotracheal intubation, no. (%) | 2 (4%) | 11 (23%) | **0.007** |
| Heparin/low molecular weight heparin, no. (%) | 10 (20%) | 16 (33%) | 0.17 |
| Vasoactive infusion, no. (%) | 2 (4%) | 13 (27%) | **0.002** |
| Macrolide antibiotic, no. (%) | 1 (2%) | 9 (19%) | **0.007** |
| Intravenous immunoglobulin infusion, no. (%) | 39 (78%) | 29 (60%) | **0.11** |

Vasoactive infusion indicates epinephrine, norepinephrine, dopamine, dobutamine, milrinone, or vasopressin

P values in bold italics indicate statistical significance <0.05
comorbidities and respiratory symptoms, and many had prolonged hospital stays culminating in a few with multiorgan failure and mortality [9]. Early reports from China focusing on infants noted the variable presence of fever and mild respiratory symptoms with none requiring intensive care or severe complications [10]. Recent reports from a European center report a high risk of cardiac involvement and ICU needs as well as elevated biomarkers in SARS COV2–affected children. Our report parallels this previous work and extends it by comparing those with versus without cardiac involvement in LATAM children. The substantial risk of coronary dilation and myocarditis in this pediatric sample deserves special attention. This difference may either reflect the selection for multisystem disease or reflect a susceptibility in this population. A minority of these children had preexisting conditions but still had high proportion involving multiple organ systems while thankfully being spared from mortality. While the proportions with preexisting conditions in cardiac and no cardiac groups were similar, we cannot comment on whether preexisting conditions were overrepresented compared to mild or asymptomatic SARS COV2 as we did not study this type of mild disease. The possible utility of neither troponin versus brain natriuretic peptide nor clinical characteristics has not been previously reported to distinguish cardiac vs noncardiac groups in multisystem disease overall. The studied characteristics’ association with cardiac involvement and severity of disease even in infants and toddlers may imply children with multisystem SARS COV2 could be proactively screened for these features in order to detect cardiac involvement and the need for intensive care.

Emergent during this observation period was MISC or alternatively PIMS [4]. MISC is defined by age <21 years, fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, multisystem (≥2) organ involvement, SARS CoV2–positive test or exposure, and no alternative plausible diagnoses [11, 12]. PIMS differs by allowing single involvement or multiorgan involvement and with or without positive SARS CoV2 testing [13]. A difficulty of the PIMS/MISC definition set involves the requirement for hospitalization which in low-resource settings may be prohibitive in a child who at presentation has not yet fully manifested the true severity of eventual disease, which then highlights the need for measurable characteristics earlier in disease which may trigger heightened suspicion for intensive management. Many of the children described in our sample would qualify for PIMS/MISC. Cardiac involvement was more common in those children with more systems involved. We found that troponin was associated with cardiac, whereas proBNP elevation was present both in cardiac and no cardiac group, suggesting proBNP may not be an ideal test for discerning cardiac group, but that troponin might be more effective. Troponin elevation and prominent accessory muscle use with abnormal chest X-ray appear to be easily ascertainable and could trigger a noninvasive cardiac workup until better modalities are identified. Likewise, ALT and thrombocytopenia are assayable in a variety of healthcare systems. Identifying the cardiac group is imperative as higher proportions of these children required intensive care. Our ROC analysis found elevated troponin level, or elevated ALT, or thrombocytopenia had strong sensitivity and negative predictive value for the ICU needs. These observational data may serve as a preliminary data for future prospective analyses and screening strategies.

This study had the strengths of being a timely investigation into children from high-risk LATAM nations in a multicenter fashion with wide variation in terms of clinical evaluation and treatment, race/ethnicity, sociodemographic background, and cultural/political milieu. These strengths allowed for the collection and comparison of uncommon characteristics like cardiac involvement and lack of IVIg availability. Limitations include the observational nature of the data collection, precluding causal inference. This analysis is subject to selection bias given the included patients tended to be those requiring hospital presentation. Therefore, the present data cannot be generalized to more mild cases. There is a risk of ascertainment bias insofar as providers in disparate locations were free to examine, test, and treat as per their own practice preferences. However, the data reported herein were at least available to all included centers, making any such differences reflective of provider decision-making rather than feasibility. The rapidly changing medical environment made precise enumeration of acute infection versus multisystem inflammatory syndrome SARS COV2 challenging; however, the precise definitions of these protean syndromes and nuances in SARS COV2 exposure make case definition difficult in general. Emerging indices of SARS COV2 involvement such as interleukins and cardiac MRI were not available at presentation of the children reported herein and thus are unavailable to document more sensitive diagnostic measures. Moreover, this analysis’ strength is contextualizing from the perspective of clinical signs and symptoms to inform clinical decision-making rather than adherence to a particular theoretical heuristic. Finally, while this analysis involves children with the rich diversity in racial and ethnic heritage present in LATAM, it may not generalize to other populations.

In summary, children from LATAM with multisystem SARS COV2 had nearly 48% cardiac involvement including in situ large artery thrombi, coronary dilation, ventricular dysfunction, valvar regurgitation, arrhythmia, and unfortunate mortality. These children were distinguished by worse respiratory effort, elevation in cardiac enzymes and ALT, thrombocytopenia, and abnormal chest radiography. These features are useful to ascertain because children with cardiac involvement went on to be more likely to need intensive cares such as invasive mechanical ventilation, vasoactive infusions, and diuretic therapy. Nonetheless, the widely available diagnostic and therapeutic modalities described herein are widely
available and informative for resource-replete and resource-poor settings around the globe.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00431-021-04052-9.

**Authors’ Contributions** JPZ conceived the study design and data collection tools, analyzed the data, formulated the manuscript, and obtained funding. RHP critically edited the manuscript, deployed and collated data collection tools, and supervised the study. All other authors contributed data to the study and critically reviewed the manuscript.

**Funding** This work was supported by the SISIAC (Society of Cardiovascular Imaging of the Interamerican Society of Cardiology) (RP) and NHLBI R01 HL148217 (JPZ).

**Data availability** Relevant, de-identified data can be made available on request.

**Code availability** Not applicable

**Declarations**

**Ethics approval** This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of CEDIMAT, Dominican Republic approved this study. Other centers either ceded review to this center or exempted from review due to de-identified, retrospective data collection.

**Consent to participate** Participant consent was exempted by the Ethics Board due to de-identified data collection and collation.

**Consent for publication** All authors consent to publication of this work. Participant consent was exempted by the Ethics Board due to de-identified data collection and collation.

**Conflict of interest** The authors declare no competing interests.

**References**

1. Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X et al (2020) COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics. 146:e202009399

2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell COVID-19 Research Consortium, Bambino DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer, Hefele J, Falzon L, Gilpin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel SM, Marks LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 323:2052–2059

3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229):1054–1062

4. Levin M (2020) Childhood multisystem inflammatory syndrome - a new challenge in the pandemic. N Engl J Med 383(4):393–395

5. Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, Armistead I, Kasawaki B, Meek J, Yousey-Hindes K, Anderson EJ, Openo KP, Weigel A, Ryan P, Monroe ML, Fox K, Kim S, Lynfield R, Bye E, Shrum Davis S, Smelser C, Barney G, Spina NL, Bennett NM, Felsen CB, Billing LM, Shiltz J, Sutton M, West N, Talbot HK, Schaffner W, Risk I, Price A, Brammer L, Fry AM, Hall AJ, Langley GE, Garg S, COVID-NET Surveillance Team, COVDC-NET Surveillance Team, Coates A, Daily Kirley P, Libby T, Roland J, Alden N, Herlihy R, McAllferty S, Clogher P, Kayalagouli H, Maslar A, Misioroski A, Nicolai L, Olson D, Parisi C, Fawcett E, Gretzinger S, Lengacher K, Williams J, Blythe D, Brooks A, Park R, Wilson M, Comos-Sabetti K, Danila R, Cline C, Angeles K, Eisenberg N, Flores K, Habrun C, Hancock E, Khanian S, Novi M, Phipps E, Salazar-Sanchez Y, Dufort E, Muse A, Bushley S, Gaitan M, Kurtz RA, Owusu-Domney A, Snyder L, Michaels E, Seeley K, Markus T, Chatelain R, George A, Hill M, McCullough L, Spencer M, Swain A, McCaffrey K, Holstein R, Meador S, Wortham J (2020) Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR Mortal Wkly Rep 69(32):1081–1088

6. Raharja A, Tamara A, Kok LT (2020) Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2020 Nov 12:1–10

7. Alsaied T, Tremoulet AH, Burns JC, Saidi A, Dionne A, Lang SM, Newburger JW, de Ferranti S, Friedman KG (2021) Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation. 143(1):78–88

8. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J et al (2020) SARS-CoV-2 infection in children. N Engl J Med 382(17):1663–1665

9. Shekerdemian LS, Mahmood NR, Wolffe KK, Riggs BJ, Ross CE, McKiernan CA et al (2020) Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 174:868

10. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ (2020) Novel coronavirus infection in hospitalized infants under 1 year of age in China. Jama. 323:1313–1314

11. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MFB, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jagg J, Oster ME, Zackai SP, Gille J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doyzman S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM, Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hefele J, Halasa NB, Patel MM, Randolph AG, Overcoming COVID-19 Investigators, CDC COVID-19 Response Team (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 383(4):334–346

12. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Routledge J, Barranco MA, Maxted AM, Rosenberg ES, Easton D, Udo T, Kumar J, Pulver W, Smith L, Hutton B, Bloch D, Zucker H, New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team (2020) Multisystem inflammatory syndrome in children in New York State. N Engl J Med 383(4):347–358

13. Whittaker E, Barnford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramanarayan P, Fraisse A, Miller O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J, Burns JC, Lyall H, Levin M, for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia (2020) Clinical characteristics of 58 children with a pediatric inflammatory multisystem
syndrome temporally associated with SARS-CoV-2. JAMA. 324: 259–269

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Ricardo Pignatelli¹ · Clara Vazquez Antona² · Ivan Romero Rivera³ · Patricia Alvarez Zenteno⁴ · Yanet Toribio Acosta⁵ · Manuel Huertas-Quíñones⁶ · Carlos Alvarez Murillo⁷ · Franklin Mendoza Torres⁷ · Carlos Fernandez Cabalin⁸ · Ana Galván Camacho⁹ · Alex Alcántara Pérez¹⁰ · Ana Braga Lombardi¹¹ · Andressa Mussi Soares¹² · Carolina Torres Garcia¹³ · Cibelle Teixeira Borges¹⁴ · Claudia Natalia Villalba¹⁵ · Cristhian Ramirez Lechado¹⁶ · Deborah Trevisan Dias¹⁷ · Diana Aravena Morales¹⁸ · Elizabeth Mora Copete¹⁹ · Guillermo Larios Goldenberg²⁰ · Jahaira Sussety Salazar²¹ · Jessica Alchundia Moreira²¹ · Junko Asakura²² · Karla Solórzano Sabando²¹ · Klebia Castello Branco²³ · Lida Toro Rosas²⁰ · Magna Pereira Duarte²⁴ · María Jiménez Carbajal²⁵ · Martha Rubio Hernandez²⁶ · Moisés Mier Martínez²⁷ · Nancy Garay Echeverría²⁸ · Olga Maza Caneva²⁹ · Patricia Romero Sepulveda³⁰ · Paulina Agurto Díaz¹⁸ · Ruth Rugel Pluas³¹ · Theo Contreras Alvarado³² · Lorena Tapia Faundes³³ · Yeny Briones Diaz¹⁸ · Justin P. Zachariah¹

Ricardo Pignatelli
cardiop@bcm.edu

Clara Vazquez Antona
cvazquezant@yahoo.com.mx

Ivan Romero Rivera
irrivera@uol.com.br

Patricia Alvarez Zenteno
pazenteno@yahoo.com

Yanet Toribio Acosta
jantor85@gmail.com

Manuel Huertas-Quíñones
manuelhuertasmd@gmail.com

Carlos Alvarez Murillo
docalvarezm@hotmail.com

Franklin Mendoza Torres
franklinmendozaipnre@gmail.com

Carlos Fernandez Cabalin
cfernandez@sochicar.cl

Ana Galván Camacho
dra.karen.galvan.alergologa@gmail.com

Alex Alcántara Pérez
alexalcantarap@gmail.com

Ana Braga Lombardi
analuzabragabm@hotmail.com

Andressa Mussi Soares
amussisoares@gmail.com

Carolina Torres Garcia
c Torres.2278@gmail.com

Cibelle Teixeira Borges
cibeltb@gmail.com

Claudia Natalia Villalba
villalbacn76@gmail.com

Cristhian Ramirez Lechado
Cristinoram@hotmail.com

Deborah Trevisan Dias
trevisancardio@gmail.com

Diana Aravena Morales
dianaaravenam@gmail.com

Elizabeth Mora Copete
elinorac@gmail.com

Guillermo Larios Goldenberg
글리어몬드@uc.cl

Jahaira Sussety Salazar
susety22@hotmail.com

Jessica Alchundia Moreira
dr.jessicaneumoinfantil@gmail.com

Junko Asakura
junkoxabo@yahoo.com.br

Karla Solórzano Sabando
drakarlasolorzano@gmail.com

Klebia Castello Branco
klebiach@gmail.com

Lida Toro Rosas
lidatoro@gmail.com

Magna Pereira Duarte
magnardo@hotmail.com

Maria Jiménez Carbajal
mgjcemd@yahoo.com.mx

Martha Rubio Hernandez
martharubio2003@yahoo.com.mx

Moisés Mier Martínez
drimier@hotmail.com

Nancy Garay Echeverría
nancygareche@hotmail.com

Olga Maza Caneva
omazacaneva@gmail.com

Patricia Romero Sepulveda
patriciar_2487@hotmail.com
Paulina Agurto Díaz
paulinadoc@gmail.com

Ruth Rugel Pluas
mipretty_rut@hotmail.com

Theo Contreras Alvarado
theoyca@hotmail.com

Lorena Tapia Faundes
lorenaisabeltapia@gmail.com

Yeny Briones Diaz
yeny.brione@gmail.com

1 Section of Pediatric Cardiology, Department of Pediatrics, Baylor
College of Medicine, Texas Children’s Hospital, 6651 Main St
Legacy Tower 20th Floor, Houston, TX 77030, USA

2 Instituto Nacional de Cardiología Ignacio Chavez, Ciudad de
México, México

3 Universidad Federal de Alagoas, Maceio, Brazil

4 Hospital Dr. Roberto del Río, Santiago, Chile

5 CEDIMAT, Santo Domingo, Dominican Republic

6 Fundación Cardioinfantil Cardiology Institute, Bogota, Colombia

7 Instituto Nacional de Salud del Niño San Borja, Lima, Perú

8 Clínica Santa María, Santiago, Chile

9 Hospital Militar de Especialidades, Ciudad de México, México

10 Complejo Asistencial Dr. Sótero del Río, Santiago, Chile

11 Universidad Federal do Rio Grande do Norte, Natal, Brazil

12 Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de
Itapemirim, Brazil

13 Centro Pneumológico Olaya, Bogotá, Colombia

14 Hospital São Camilo Curitiba, Fortaleza, Brazil

15 Hospital Británico, Buenos Aires, Argentina

16 Hospital Solidaridad, Managua, Nicaragua

17 Real Hospital Português de Beneficência, Recife, Brazil

18 Hospital Dr. Luis Calvo Mackenna, Santiago, Chile

19 Clínica La Colina, Bogotá, Colombia

20 Pontificia Universidad Católica de Chile, Santiago, Chile

21 Hospital de Especialidades, Portoviejo, Ecuador

22 Hospital UNIMED, Maceio, Brazil

23 Universidade Federal do Ceará, Fortaleza, Brazil

24 Hospital Geral do Estado de Alagoas, Maceio, Brazil

25 Centro Médico ABC, Ciudad de México, México

26 Hospital Central Dr. Ignacio Morones, San Luis Potosí, México

27 Centro Pediátrico del Corazón ABC-Kardias, Ciudad de
México, México

28 Hospital General Pediatrónico Acosta Ñu, Asunción, Paraguay

29 Clínica General del Norte, Barranquilla, Colombia

30 CEDIMAT, San Cristóbal, Dominican Republic

31 Omnihospital, Guayaquil, Ecuador

32 IMSS Hospital de Cardiología No. 34, Monterrey, México

33 Departamento de Pediatria Norte, Facultad de Medicina,
Universidad de Chile, Santiago, Chile